BIOMAT Database Logo BIOMAT Database Logo

Continuous glucose monitoring: physiologic and pathophysiologic significance. 2004

C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Clinic of Diabetes, Institute of Diabetes, Nutrition and Metabolic Diseases N. Paulescu, Bucharest, Romania.

Diabetes mellitus is a complex disorder of the energy metabolism. In the present paper, we have tried to illustrate the changes in the regulation of blood glucose levels encountered in the two main types of diabetes: Type 2 (T2DM) and Type 1 (T1DM) diabetes mellitus, compared with healthy, non-diabetic subjects. For this we used the MiniMed CGMS (Continuous Glucose Monitoring System) which allows the continuous in vivo blood glucose measurement over a 3-day period. The study group comprised 19 diabetic patients (14 T1DM and 5 T2DM cases) and 4 non-diabetic controls. The recording in normal subjects showed a glycemic variation between 46 and 118 mg/dl, suggesting the existence of a strong and efficient glycemic control mechanism. In T2DM patients, both on diet only or on oral antidiabetic treatment, the oscillation of blood glucose levels was significantly higher compared to that recorded in non-diabetic subjects. In T1DM patients with stable metabolic control blood glucose fluctuations were comparable with those recorded in long-term type 2 diabetic patients but the "mean" values of blood glucose over 72 hours were lower. The CGMS is a valuable tool in the detection of unrecognized hypoglycemic episodes and hyperglycemic postprandial peaks and allows the patient and the health care team to adjust the treatment regimen in order to improve glycemic control. From our point of view, the CGMS could offer valuable information for the knowledge of glycemic regulation in normal people and for the diabetogenic mechanisms in prediabetic IGT and IFG patients.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D010880 Piperidines A family of hexahydropyridines.
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus

Related Publications

C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
[Colloid osmotic pressure--physiologic, pathophysiologic and clinical significance].
January 1988, Anaesthesiologie und Reanimation,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
[G-proteins. Significance for physiologic and pathophysiologic processes].
August 1995, Medizinische Monatsschrift fur Pharmazeuten,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Lysosomal enzymes in biological fluids: physiologic and pathophysiologic significance.
March 1979, Digestive diseases and sciences,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
[Physiologic and pathophysiologic significance of antimicrobial (host defensive) small peptides].
December 2008, Orvosi hetilap,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
[The physiologic and pathophysiologic significance of the pulmonary interstitial space].
March 1972, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Physiologic monitoring of blood glucose.
June 1963, California medicine,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Continuous Physiologic Monitoring: False Alarms and Overdiagnosis.
June 2018, Journal of hospital medicine,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Implantable nanosensors: toward continuous physiologic monitoring.
February 2014, Analytical chemistry,
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
Continuous glucose monitoring.
March 2023, BMJ (Clinical research ed.),
C Ionescu-Tîrgovişte, and C Guja, and S Ioacără, and Dana Dumitrescu, and Ilinca Tomescu
[Continuous glucose monitoring].
May 2012, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!